FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C	20549	
vasiliilululi.	D.C.	20049	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Lawton Alison Frances					2. Issuer Name and Ticker or Trading Symbol X4 Pharmaceuticals, Inc [ XFOR ]									(CI	neck all app	nship of Reporting Poll applicable) Director		rson(s) to Is 10% Ov	
(Last)	(Fir	st) (N	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/10/2024									Office below	er (give title v)		Other (s below)	specify
C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	e)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person					
(Street)	N MA	A 0	2134		Rul	Form filed by More than One Reporting Person  Rule 10b5-1(c) Transaction Indication											orting		
(City)	(Sta	ate) (Z	Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.									uction or writt	ten pla	n that is inter	nded to	
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	, Dis	posed of	, or I	Bene	eficia	ally Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day						Exec if an	Deemed cution Date, y nth/Day/Year)		3. Transaction Code (Instr. 8) 4. Securitie Disposed (5)		es Acquired (A) o Of (D) (Instr. 3, 4		(A) or 3, 4 ar	Benefi	ies cially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
										v	Amount	(A (D	() or ()	Price	Transa	action(s) 3 and 4)			(Instr. 4)
Common Stock 06/10/2					2024				A		45,000(1	5,000(1)		\$0	96,667			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative   Conversion   Date   Execution Date, ecurity   or Exercise   (Month/Day/Year)   if any			4. Transaction Code (Instr. 8)		of	r osed (: 3, 4	Expiration Da (Month/Day/Y		ite	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		,	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	or Nun of	ount nber res					

## **Explanation of Responses:**

1. Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

## Remarks:

/s/ Adam S. Mostafa, attorneyin-fact 06/11/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.